Identification

Generic Name
Amineptine
DrugBank Accession Number
DB04836
Background

The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.

Type
Small Molecule
Groups
Illicit, Withdrawn
Structure
Thumb
Weight
Average: 337.463
Monoisotopic: 337.204179113
Chemical Formula
C22H27NO2
Synonyms
  • Amineptine
  • Amineptino
  • Amineptinum

Pharmacology

Indication

For the treatment of depression.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Amineptine is an atypical tricyclic antidepressant.

Mechanism of action

Amineptine selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.

TargetActionsOrganism
USodium-dependent noradrenaline transporterNot AvailableHumans
USodium-dependent serotonin transporterNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic.

Route of elimination

Not Available

Half-life

48 minutes for the parent drug and 2.5 hours for the metabolites.

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Amineptine is combined with 1,2-Benzodiazepine.
AcarboseAmineptine may decrease the hypoglycemic activities of Acarbose.
AcebutololAmineptine may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Amineptine is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Amineptine.
AcetohexamideAmineptine may decrease the hypoglycemic activities of Acetohexamide.
AcetophenazineThe serum concentration of Amineptine can be increased when it is combined with Acetophenazine.
Acetylsalicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Acetylsalicylic acid.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid alcohol.
  • Avoid St. John's Wort.
  • Limit caffeine intake.
  • Take with food. Food reduces irritation.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Amineptine hydrochlorideA5P604A12R30272-08-3VDPUXONTAVMIKZ-UHFFFAOYSA-N
International/Other Brands
Directim / Maneon / Neolior / Provector / Survector (Servier) / Viaspera

Categories

ATC Codes
N06AA19 — Amineptine
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
27T1I13L6G
CAS number
57574-09-1
InChI Key
ONNOFKFOZAJDHT-UHFFFAOYSA-N
InChI
InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)
IUPAC Name
7-({tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}amino)heptanoic acid
SMILES
OC(=O)CCCCCCNC1C2=CC=CC=C2CCC2=CC=CC=C12

References

Synthesis Reference

Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale. Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale.

US3758528
General References
  1. Vaugeois JM, Corera AT, Deslandes A, Costentin J: Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor. Pharmacol Biochem Behav. 1999 Jun;63(2):285-90. [Article]
  2. Grupper C: [New iatrogenic acne: acne caused by amineptin (Survector)]. Ann Dermatol Venereol. 1988;115(11):1174-6. [Article]
  3. Thioly-Bensoussan D, Charpentier A, Triller R, Thioly F, Blanchet P, Tricoire N, Noury JY, Grupper C: [Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases]. Ann Dermatol Venereol. 1988;115(11):1177-80. [Article]
  4. Vexiau P, Gourmel B, Husson C, Castot A, Rybojad M, Julien R, Fiet J, Puissant A, Cathelineau G: [Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases]. Ann Dermatol Venereol. 1988;115(11):1180-2. [Article]
  5. Teillac D, Weber MJ, Lowenstein W, de Prost Y: [Acne caused by Survector]. Ann Dermatol Venereol. 1988;115(11):1183-4. [Article]
KEGG Drug
D07335
PubChem Compound
34869
PubChem Substance
46509012
ChemSpider
32091
BindingDB
50292474
RxNav
17698
ChEBI
32499
ChEMBL
CHEMBL418995
ZINC
ZINC000002001740
Therapeutic Targets Database
DCL000340
Wikipedia
Amineptine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226-230Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale
Predicted Properties
PropertyValueSource
Water Solubility0.000305 mg/mLALOGPS
logP1.99ALOGPS
logP2.74ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)4.41ChemAxon
pKa (Strongest Basic)9.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity101.21 m3·mol-1ChemAxon
Polarizability39.7 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.927
Blood Brain Barrier+0.9384
Caco-2 permeable-0.5548
P-glycoprotein substrateNon-substrate0.5457
P-glycoprotein inhibitor INon-inhibitor0.9324
P-glycoprotein inhibitor IINon-inhibitor0.8538
Renal organic cation transporterNon-inhibitor0.6998
CYP450 2C9 substrateNon-substrate0.7559
CYP450 2D6 substrateNon-substrate0.7653
CYP450 3A4 substrateNon-substrate0.5897
CYP450 1A2 substrateNon-inhibitor0.5434
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.7593
CYP450 2C19 inhibitorNon-inhibitor0.8446
CYP450 3A4 inhibitorNon-inhibitor0.7073
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9165
Ames testAMES toxic0.6805
CarcinogenicityNon-carcinogens0.8651
BiodegradationNot ready biodegradable0.7096
Rat acute toxicity2.9526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9341
hERG inhibition (predictor II)Inhibitor0.6018
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at September 12, 2007 09:05 / Updated at December 04, 2021 10:43